Table I.

Univariate analysis of the association of baseline characteristics with ORR and pCR.

Characteristics	No.	ORR	P-value	pCR	P-value
No. of patients	68
Median age, years (range)	45 (35–60)
Tumor diameter, mm (range)	45 (25–80)
Menopausal status
Premenopausal	32	81% (26/32)	0.587a	19% (6/32)	0.724a
Postmenopausal	36	86% (31/36)		22% (8/36)
ECOG performance
0	44	86% (38/44)	0.670b	23% (10/44)	0.782b
1	24	79% (19/24)		17% (4/24)
Clinical nodal status
Negative	18	78% (14/18)	0.661b	17% (3/18)	0.889b
Positive	50	86% (43/50)		22% (11/50)
Stage
II (T≥5 cm)	30	80% (24/30)	0.668b	20% (6/30)	0.915a
III	38	87% (33/38)		21% (8/38)
Survivin
Negative	18	61% (11/18)	0.0072c	0% (0/18)	0.0292a
Positive	50	92% (46/50)		28 (14/50)
Ki-67
Negative	16	63% (10/16)	0.0242c	0% (0/16)	0.0482a
Positive	52	90% (47/52)		27% (14/52)
Estrogen-receptor
Negative	31	87% (27/31)	0.502a	29% (8/31)	0.330a
Positive	37	81% (30/37)		16% (6/37)
No. of cycles
4	39	85% (33/39)	1.0b	21% (8/39)	0.986a
5–6	29	83% (24/29)		21% (6/29)
Tumor type
Invasive ductal	60	87% (52/60)	0.218b	25% (13/60)	0.891b
Invasive lobular	8	63% (5/8)		13% (1/8)
Tumor grade
I/II	28	71% (20/28)	0.0472c	11% (3/28)	0.092a
III	40	93% (37/40)		28% (11/40)
PgR
Negative	37	28% (11/40)	0.189a	22% (8/37)	0.818a
Positive	31	77% (24/31)		19% (6/31)
HER2 status
0 to 1+	50	88% (44/50)	0.236b	24% (12/50)	0.412b
2+ to 3+	18	72% (13/18)		17% (2/18)

^aP, Pearson's Chi-square test,

^bP, continuity correction test,

^cP<0.05.

ORR, overall clinical response rate; pCR, pathological complete response; PgR, progesterone receptor. ECOG, Eastern cooperative oncology group; HER2, human epidermal growth factor receptor-2.